Volume 25, Number 1—January 2019
CME ACTIVITY - Research
Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004–2010
Alexander C. Ewing
, Nicole L. Davis, Dumbani Kayira, Mina C. Hosseinipour, Charles van der Horst, Denise J. Jamieson, Athena P. Kourtis, and for the BreastfeedingAntiretrovirals and Nutrition study team
, Nicole L. Davis, Dumbani Kayira, Mina C. Hosseinipour, Charles van der Horst, Denise J. Jamieson, Athena P. Kourtis, and for the BreastfeedingAntiretrovirals and Nutrition study team
Table 5
Cox proportional hazard ratio estimates for associations between prescriptions for antibacterial drugs and other variables in the Breastfeeding, Antiretrovirals and Nutrition study, Malawi 2004–2010
| Factor | Hazard ratio (95% CI) |
|---|---|
| Cotrimoxazole preventive therapy | 0.57 (0.52–0.61) |
| Malaria season (Oct–Apr) |
0.98 (0.91–1.05) |
| Treatment group | |
| Maternal antiretrovirals | 0.85 (0.78–0.93) |
| Infant nevirapine |
0.90 (0.82–0.98) |
| Nutritional supplement | 1.05 (0.98–1.12) |
| Maternal CD4+ T-cell count at delivery, cells/μL | 1.15 (0.96–1.38) |
| Maternal HIV viral load during pregnancy, log copies/mL | 1.02 (1.003–1.04) |
| Maternal age, y |
1.01 (0.998–1.01) |
| Maternal education | |
| None | Reference |
| Primary | 0.92 (0.83–1.03) |
| Secondary | 0.99 (0.89–1.11) |
| Tertiary |
0.93 (0.65–1.32) |
| Male sex | 1.09 (1.02–1.17) |
| Infant birthweight, kg |
1.17 (1.06–1.28) |
| Age category, mo | |
| Birth–1 mo | Reference |
| 1–3 | 0.80 (0.67–0.95) |
| 3–6 | 0.63 (0.53–0.76) |
| 6–12 | 0.48 (0.40–0.58) |
1Team members are listed at the end of this article.
Page created: December 12, 2018
Page updated: December 12, 2018
Page reviewed: December 12, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.